Xeljanz tofacitinib

Xeljanz's oral convenience drives strong trial intent, but the first 4-8 weeks are the highest abandonment window -- infection events and GI side effects are the two dominant drop-off triggers a peer-mentorship program could intercept in real time.

• UC patients report markedly higher satisfaction (avg 7.2-7.5/10) than RA patients (avg 5.3-5.8/10), signaling a clear indication-specific messaging opportunity for the commercial team.
• The first 4-8 weeks are the critical adherence fault line: patients who push through early GI and infection events often become vocal advocates, while early discontinuers become detractors.
• Cost and insurance navigation -- especially the Medicare Part D cliff -- is a top-of-mind barrier that Pfizer's XelSource co-pay program resolves for most commercially-insured patients but not for Medicare beneficiaries.
• Boxed-warning fear (MACE, cancer, thrombosis) and active MDL litigation create HCP and patient anxiety that peer stories from long-term tolerators are uniquely positioned to address.